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ABSTRACT
Development of a Predictive Model for Frailty Utilizing Electronic Health Records
MAY 2022
KYE E. PORONSKY, B.A. HOFSTRA UNIVERSITY
M.A., UNIVERSITY OF HARTFORD
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Brian Whitcomb
Frailty is a multifaceted, geriatric syndrome that is associated with age-related
declines in functional reserves resulting in increased risks of in-hospital death,
readmissions and discharge to nursing homes. The risks associated with frailty highlights
the need for providers to be able to quickly, and accurately, assess someone’s frailty level.
Previous studies have shown that bedside clinician assessment is not a reliable or valid way
to determine frailty, meaning that a more reliable, valid and concise method is needed. We
developed a prediction model using discharge ICD-9/ICD-10 diagnostic codes and other
demographic variables to predict Reported Edmonton Frail Scale scores. Participants were
from the Baystate Frailty Study, a prospective cohort design study among elderly patients
greater than 65 years old who were admitted to a single academic medical center between
2014 and 2016. Three different predictive models were completed utilizing the LASSO
approach. The adjusted r-square increased across the three models indicating an increase
in the predictive ability of the models. In this study of 762 hospitalized patients over the
age of 65 years old, we found that a frailty prediction model that included ICD codes only
had a poor prediction ability (adjusted r-square=0.10). The prediction ability improved 2fold after adding demographic information, a comorbidity score and interaction terms
(adjusted r-square=0.26). This study provided additional insights into the development of
an automatic frailty assessment, something which is currently missing from clinical care.
Keywords: frailty, prediction model, ICD codes, electronic health record, Edmonton Frail
Scale
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CHAPTER 1
INTRODUCTION
1.1 Public Health Impact of Frailty
In 2014, over 12 million hospitalizations were reported for patients over the age
of 65 years, accounting for 35% of all hospitalizations.1 For some older people, hospital
admission is associated with an increased risk of harm over and above the presenting
condition.2 Several attempts have been made to identify people at high risk of poor
outcomes, many focusing on frailty and multimorbidity.3 Frailty can be defined as “a
clinical state characterized by an increased vulnerability of an organism to stressors,
exposing individuals to negative health-related outcomes”.4 As such, frailty is a
multifaceted, geriatric syndrome that is associated with age-related declines in functional
reserves resulting in increased risks of in-hospital death, readmissions and discharge to
nursing homes.4 The risks associated with frailty highlights the need for providers to be
able to quickly, and accurately, assess someone’s frailty level. In addition, with the aging
of the United States population and increasing longevity of older adults, frailty is
expected to increase in prevalence. Previous studies have shown that bedside clinician
assessment is not a reliable or valid way to determine frailty5, meaning that a more
reliable, valid and concise method is needed. The ability to predict frailty is crucial for
providing meaningful interventions for patients, keeping them out of the hospital and
reducing mortality and morbidity, however operationally defining, and ultimately
measuring frailty has been shown to be difficult.
There are five widely accepted physical traits that indicate frailty: weight loss of
more than 10 pounds over 1-year, frequent exhaustion, low levels of activity, slow gait,
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and poor grip strength.6,7 While assessing physical traits can predict frailty6,7, it is not
always feasible to collect this data from patients, which again underscores the need for
other types of assessments. While previous assessment tools have reported high validity
and reliability in assessing frailty8, many of these tools are time-consuming and require
providers or other healthcare personnel to complete the interviews in-person with patients
and/or caretakers. Due to these different constraints, most hospitalized elderly patients
are not adequately assessed for frailty. While limitations in physiological reserves are
generally not modifiable, the ability to identify frail patients quickly and accurately could
allow providers to use targeted interventions that can positively influence the patient’s
outcome, again, for example, lowering the risk of readmission to the hospital and/or
mortality. Such frailty-appropriate interventions could include geriatric or palliative
consultations, admissions to geriatric wards, early interventions to increase mobilization,
medication reconciliation by a geriatric pharmacist, delirium prevention, discussions
regarding goals of care, and early planning for discharge.9,10 Overall, there is a need for a
way to predict which patients accurately and quickly are at risk of being categorized as
frail so appropriate interventions can be implemented.
1.2 Previous predictive models and assessments of frailty
Previous research studies have been able to use clinical data to predict different
scores on clinical assessment tools, for example, predicting impaired glucose tolerance
for those with a diagnosis of diabetes11, cardiac risk12, and neurosurgical outcomes.13
The ability to predict different outcomes and risks utilizing clinical data would allow
providers to be able to give more appropriate care, and would also save time and
resources, giving providers and other healthcare personnel the time to give target
interventions. Previous predictive models of frailty have used ICD-9/ICD-10CM
2

diagnostic codes7,10,14–16; however, these models included outpatient settings and/or were
not validated against a reference measure of frailty such as in-person assessments and did
not include patients hospitalized in the United States. Being able to predict a validated
assessment could add validity and reliability to these prediction models, potentially
making them more valuable and useful. In addition, the lack of studies in the United
States demonstrates the need for this sort of prediction model to be applied to this
population, as healthcare in the United States may differ from the other countries in
which these projects were previously completed.
As noted above, previous work supports the notion that electronic health record
(EHR) data can be utilized to predict the outcome of frailty7,10,16, however, these models
could be strengthened by utilizing a validated measure of frailty as the outcome.7,8,10,14–20
Further, tools that are used to measure frailty vary widely across their individual
measurements of frailty, making the tools less useful because the operational definition of
frailty can change from tool to tool.21 The variables in and of themselves can be valid
measures of frailty, however, when combined into singular tools, consistency could lead
to a more reliable and valid measure. In addition, one scoping review found that only a
few of these assessments were reliable22, highlighting the need for a better method in
which to predict frailty.14
1.3 Study objectives, significance, and innovation
This project aimed to develop a model that utilizes ICD-9/ICD-10 diagnostics
codes to predict a validated, in-person assessment of frailty, the Reported Edmonton
Frailty Scale (REFS). As noted previously, other studies have examined outpatient
populations from outside the United States and did not utilize a validated in-person
assessment of frailty. This project addresses some of those gaps by utilizing an inpatient
3

population, in the United States, and is using the REFS, which is a validated measure, as
the outcome. The REFS is a scale that can be completed at the bedside by any individual
and measures frailty across domains that are generally found in all geriatric
assessments.23
Specific Aim: To develop a predictive model that combines demographic and
administrative variables to predict frailty.
Hypothesis: The variables available from the EHR, specifically ICDs from
discharge, will predict frailty.
In this project, we leveraged the information from a unique database from the
Baystate Frailty Study (BFS) of 1100 hospitalized elders with frailty determined by inperson assessment using the REFS. For this study, frailty was defined using the subjects’
score on the REFS, with a higher score indicating higher levels of frailty. We utilized
demographic and administrative variables available from the subject’s
admission/discharge visit and from the BFS database to develop a prediction model for
frailty assessed by the REFS. The overall aim of the project is to ascertain if ICD-9/ICD10 codes and other clinical variables can be utilized to accurately predict frailty scores on
the REFS.

4

CHAPTER 2
METHODS
2.1 The Baystate Frailty Study
We developed a prediction model using discharge ICD-9/ICD-10 diagnostic
codes and other demographic variables to predict REFS scores in participants of the BFS.
The BFS was a prospective cohort design study among 1100 elderly patients greater than
65 years old who were admitted to Baystate Medical Center (BMC) in Springfield,
Massachusetts between January 1, 2014, through April 30, 2016, for urgent surgeries,
trauma, elective orthopedic surgeries, and for treatment of congestive heart failure (CHF),
pneumonia (PNA) and/or chronic obstructive pulmonary disease (COPD) or other
medical conditions.
2.2 Study Population
Eligible patients for the BFS were individuals over the age of 65 who presented to
BMC for: 1) an urgent noncardiac surgical procedure that required an in-patient stay and
that was sufficiently complex to result in postoperative complications (e.g., hip fractures,
small bowel obstruction, acute cholecystitis, vascular procedures, amputations); or 2)
those with trauma, elective orthopedic surgeries (hip and knee replacement) and 3) nonsurgical patients with the 3 most common medical conditions: CHF, PNA, and COPD.
The BFS excluded individuals who had cardiac surgeries, emergent surgeries (patients
with an acute life-threatening condition necessitating immediate surgery), patients who
did not speak English (difficult to obtain consent, administer the questionnaire and
evaluate daily mental status) and patients with advanced dementia. Individuals who were
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transferred from other acute care facilities, those patients admitted to observation or to
the intensive care unit were also excluded.
A total of 1100 patients were initially enrolled into the BFS. Of these, 317
patients were excluded for missing age data (n=5), place of residence data (n=2), BMI
data (n=22), missing complete REFS (n=178), or missing both BMI and REFS (n=110).
Of the 288 patients missing REFS data, 272 of them met exclusion criteria. Twenty-one
patients had been enrolled twice, so only their first visit/admission was included, which
left a total of 762 subjects for analysis.
2.3 Assessment of Frailty
Frailty was assessed using the REFS which was administered before the surgery
or within 24 hours after admission for non-surgical patients. It was administered by
trained research staff in an in-person, bedside interview with the patient. The REFS
assesses frailty across multiple domains including cognition, self-evaluation of general
health status, functional independence, presence of social support, medication use and
adherence, nutrition, mood, incontinence, and self-reported performance. Each item is
scored 0 points (frailty absent/normal health), 1 point (minor errors or mild/moderate
impairment) or 2 points (important errors or severely impaired). The maximum REFS
score is 18 and higher scores have been shown to reflect greater frailty.24
2.4 Validity of Frailty Assessment
The REFS has been validated in other studies for use by non-geriatricians15–17 and
has been shown to have reliability measure frailty.16,18 In a previous validation study,
patients who were at least 65 years old and referred for a comprehensive geriatric
assessment were given the REFS. The REFS was administered to these patients by
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research assistants who did not have previous formal training relating to the REFS. A
random sample of these same patients was selected to do the REFS again to assess
interrater reliability.18 The REFS was shown to have a normal distribution with a high
interrater reliability (kappa= 0.77-0.84) over multiple interviewers. 16,18 The REFS also
has high internal consistency, with analyses showing a Cronbach’s alpha of 0.62.18
2.5 Predictor Variables
The main predictor variables were ICD-9/ICD-10 codes from the subject’s
discharge records after the date of enrollment. These discharge ICD-9/ICD-10 codes were
then manually categorized into 14 different frailty domains consisting of (1) debility
problems, (2) fatigue issues, (3) swallowing issues, (4) nutrition issues, (5) cognitive
issues, (6) acute confusional states, (7) incontinence, (8) chronic skin ulcers, (9) sensory
impairment, (10) impaired mobility, (11) depression problems, (12) falls, (13) fractures,
and (14) anemia, due to their clinical relevance to the outcome of frailty. This data was
collected retrospectively from the EHR and the Baystate Frailty Study (BFS)
database. These domains were identified as potential explanatory categories by the
principal investigators of the BFS through their previous analyses of the already collected
data and based on consultation with 4 geriatrician researchers. These domains were
treated as dichotomous variables (yes or no to having the ICD code present in the
discharge information) and were created by manually reviewing and assigning all
collected ICD-9/ICD-10 diagnosis codes into the frailty domains as necessary (Appendix
A). Utilizing these variables as dichotomous variables allowed for the collapsing of the
ICD codes from individual codes into the frailty domains allowing for ease of analysis.
As there were hundreds of ICD codes present from the discharge information, sorting into
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frailty domains and dichotomous variables made the data more concise. This review and
assignment were completed by two study staff members, one of whom is a hospitalist at
BMC. Any ICD-9/ICD-10 code that did not fit into one of the categories above were
removed from the analysis. Demographic variables that were assessed were age, gender,
residence at time of admission and BMI. These variables were obtained from patient
records. Finally, we also assessed the extent of comorbidity using the Gagne Comorbidity
Score. The Gagne score combines the Charlson and Elixhauser scores, both of which
have been shown to be associated with short- and long-term mortality.25
2.6 Statistical Analyses
2.6.1 Preliminary analyses
For preliminary descriptive analyses, means and standard deviations were
computed for continuous factors and frequencies distributions have been estimated for
categorical variables. To facilitate examination of factors related to the REFS, the sample
was divided into frail and non-frail patients, based on the REFS score. (This dichotomy
was only for the purposes of the data shown in Table 1. The REFS was used as a
continuous outcome variable for the predictive models.) Frail and non-frail patients were
compared using two-sample t-tests for continuous variables and Fisher's exact test for
categorical variables.
2.6.2 Development of Predictive Model
In developing the prediction model, we followed best practices for prediction model
building by splitting the data intro a training and a validation data set.26,27 To train the
predictive model, a training dataset was created by randomly selecting 75% the patient
sample. The remaining 25% formed the validation dataset. This approach was used for

8

several reasons. First, this approach minimized overly optimistic estimates in developing
(i.e., training) the prediction model. Although a stepwise linear regression approach may
be used to select a subset of predictor variables. Harrell (2012) advises against its use
because the final model can overfit the data. As a consequence, the resulting beta
coefficients will likely be poor out-of-sample predictors.28 To address these concerns, a
Least Absolute Shrinkage and Selection Operator (LASSO) approach was utilized to
train, validate, and test the model utilizing a linear regression. A LASSO approach allows
for the inclusion of all potential predictors into a single model. The LASSO will then
compute all possible models utilizing all the predictors and then select the model which
has the best outcome, dropping predictors that seem to have no statistical relation to the
outcome. Employing the LASSO approach minimizes bias arising from optimistic
estimation by minimizing estimates of the out-of-sample prediction error.29 Thus, the
LASSO approach not only can yield a more simplified, unbiased model (by removing
unnecessary variables), but also can control for collinearity among the variables. The
LASSO approach allows for the development of a more parsimonious model, it does not
report statistics commonly seen in regression models. In addition, the LASSO approach
may also remove variables that could be of interest in favor of parsimony and collinearity
concerns meaning an interact term may stay in the model while the individual predictor
may be removed.
For this project a LASSO was applied as a linear regression model since the outcome
was continuous and approximately normally distributed. In total, three LASSO models
were completed, Model 1 consisted only of the frailty domains (based on ICD-9/10 CM
codes), Model 2 consisted of frailty domains and demographics, and then the final model,

9

Model 3, included the frailty domains, demographics, the Gagne score for prediction of
comorbidities and interaction terms. A secondary, more standard linear regression model
was run utilizing the predictors identified in Model 3, the strongest LASSO model, to
assess each individual predictor in a more conventional approach. Model beta coefficients
from the training dataset were applied to the validation dataset and calibration was
assessed (i.e., model performance was measured on how accurately the model could
predict the REFS score and as such, frailty). Our primary analysis utilized the REFS
modeled as a continuous variable, however in general, a patient can be classified as frail,
using the REFS, if he or she scores at or above a cut point of 8 and as not frail if the
patient scored at or below a score of 7.
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CHAPTER 3
RESULTS
Cohort characteristics
A total of 1100 patients were initially enrolled into the BFS. Of these, 331
patients were excluded for missing BMI data (n=22), missing complete REFS (n=178)
and a few missing both BMI and REFS (n=110). Of the 288 patients missing REFS data,
272 of them met our exclusion criteria. We also had 21 patients who had been enrolled
twice, and we chose only included their first visit. Five individuals did not have an age
recorded, and another 2 were missing residence data which left a total of 762 subjects for
analysis.
To describe the study population and evaluated characteristics associated with
frailty, For the purposes of Table 1, subjects were divided into non-frail and frail
categories, though for analysis the REFS was used as a continuous variable. The average
REFS score was 5.9 for the population, with non-frail individuals having an average
score of 3.8 and frail individuals having an average score of 10.1 (Figure 1).
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Figure 1. Histogram of Actual REFS Score
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The overall study population had an average age of 78.6 years, with frail
individuals being slightly older (80.2 years) than non-frail individuals (77.8 years).
Gender was almost equally distributed across both groups, and most of the study
population were white (670 participants). As illustrated in Table 1, most of the sample
were on Medicare, which was consistent across both the frail and non-frail groups. Those
in the frail category were more likely be readmitted within 30-days and were also more
likely to be dead within 1 year of their visit when compared to those in the non-frail
category. T-test analyses showed several significant relationships between the clinical
variables of interest and the dichotomized REFS score (Table 1). Most clinical
characteristics were significantly associated with the REFS except for BMI when utilized
as a continuous variable, however when BMI was used ca a categorical variable (normal,
overweight, etc.), there was statistical significance. Similarly, almost all the frailty
domains, except for debility (p=0.45) were also significantly associated with the REFS.
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Table 1. Patient’s characteristics by frailty categories
Total Not Frail (0-7)
Clinical Characteristic
(n = 762)
(n=501)
Age (years), mean (SD)
78.6 (7.8)
77.8 (8.1)
BMI kg/m2, mean (SD)
28.3 (7.0)
28.4 (6.9)
REFS score, mean (SD)
5.9 (3.7)
3.8 (2.3)
n (%)
n (%)
Patient Type
Urgent Surgery
191 (25.1) 159 (31.7)
Medical
473 (62.2) 250 (49.9)
Elective Surgery
97 (12.8)
92 (18.4)
Gender
Female
441 (57.9) 288 (57.5)
Male
321 (42.1) 213 (42.5)
Race/Ethnicity
Asian
3 (0.4)
1 (0.2)
Black
44 (5.8)
19 (3.8)
Hispanic
34 (4.5)
17 (3.4)
Other
3 (0.4)
3 (0.6)
Unknown
8 (1.1)
8 (1.6)
White
670 (87.9) 453 (90.4)
BMI Categories
< 18.5
25 (3.3)
13 (2.6)
>=18.5 to < 25
239 (31.4) 153 (30.5)
>= 25
498 (65.4) 335 (66.9)
Residence
Home
682 (89.5) 468 (93.4)
Assisted Living
47 (6.1)
23 (4.6)
Nursing Home
33 (4.3)
10 (2)
Discharge Disposition
Home or Home with Services 410 (53.8) 289 (57.3)
Nursing Home
313 (41.1) 186 (36.9)
Rehabilitation
27 (3.5)
20 (4.0)
Expired or Hospice
12 (1.6)
9 (1.8)
Death
No
465 (61)
345 (68.9)
Yes
297 (39)
156 (31.1)
Readmitted w/in 30 Days
No
662 (86.9)
456 (91)
Yes
100 (13.1)
45 (9)
Insurance
Other
50 (6.6)
41 (8.2)
Medicare
712 (93.4) 460 (91.8)
13

Frail (8-16)
(n=261)
80.2 (7.3)
28.2 (7.4)
10.1 (1.8)
n (%)

p-value
< 0.001
0.8

< 0.0001
32 (12.3)
223 (85.8)
5 (1.9)
0.06
153 (58.6)
108 (41.4)
< 0.0001
2 (0.8)
25 (9.6)
17 (6.5)
0 (0)
0 (0)
217 (83.1)
0.0026
12 (4.6)
86 (33.0)
163 (62.5)
< 0.0001
214 (82)
24 (9.2)
23 (8.8)
< 0.0001
126 (47.6)
128 (48.3)
8 (3.0)
3 (1.1)
< 0.0001
120 (46)
141 (54)
< 0.0001
206 (78.9)
55 (21.1)
0.0046
9 (3.5)
252 (96.6)
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Predictive models
Three different models were completed utilizing the LASSO approach (Table 2).
The adjust r-square increased across the three models indicating an increase in the
predictive ability of the model. Falls and debility were negatively associated with the
REFS score across the models. Table 2 shows the results of the variable selection for the
three models. Each variable that was included in the model has the coefficient and rank
included in the table, such that the higher the rank, the more strongly associated with the
REFS the variable is. The coefficient also demonstrates the strength of the association
with the REFS score.
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Model 1. Model 1 included only the Frailty Domains to predict the REFS. The
analysis kept 7 of 14 domains in the final model including fatigue, acute confusion,
incontinence, chronic skin ulcers, depression problems, falls and anemia, but excluding
fractures, cognitive issues, debility, nutritional issues, sensory impairment, impaired
mobility, and swallowing issues (Figure 2). The overall adjusted r-square for model 1
was 0.10. In Figure 2, the selected cut-off for the predictors to be included is
demonstrated by the “Selected Step” line drawn at “acute confusion”. All predictors up to
that line were selected by the LASSO to remain in the model, while the predictors after
the line were not selected by the LASSO analysis.
Figure 2. LASSO Model 1- Frailty Domains Only

Model 2. The second model included demographic data, age, gender,
residence, BMI, the 14 frailty domains, and the Gagne Comorbidity Score. In the second
model, the LASSO approach excluded 7 of the variables (gender, impaired mobility,
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incontinence, swallowing issues, cognitive issues, BMI, and sensory impairment), while
retaining the following variables: age, residence, depression problems, falls, fatigue,
fractures, anemia, nutritional issues, acute confusion, chronic skin ulcers and debility
problems. The adjusted r-square for this model was notably higher at 0.25. (Figure 3). In
Figure 3, the selected cut-off for the predictors to be included is demonstrated by the
“Selected Step” line drawn at “debility”. All predictors up to that line were selected by
the LASSO to remain in the model, while the predictors after the line were not selected
by the LASSO analysis.
Figure 3. LASSO Model 2- Frailty Domains and Demographics

Model 3. The final model included all demographic variables, 14 frailty domains,
the Gagne Comorbidity Score, and included the following interaction terms: depression
by age, falls by age, and depression by gender. These interaction terms have been shown
in previous literature to be correlated with frailty and as such were included as
interactions in the final model. In this model, 12 variables and 2 interaction terms met the
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criteria for inclusion, age, residence, debility, fatigue, nutritional issues, acute confusion,
chronic skin ulcers, impaired mobility, falls, fractures, anemia, and the Gagne score,
along with the interactions between gender and depression problems and age and
depression problems (Figure 4).
Figure 4. LASSO Model 3- Frailty Domains, Demographics, and Interaction Terms

Figure 4 demonstrates the final model selected by the LASSO. Predictors that are
listed before the “Selected Step” line were included in the final model, while the others
were excluded. The blue and red lines demonstrate the training (75% of the sample) and
test (25% of the sample) datasets and the impact that adding in each predictor has at each
step. The figure demonstrates that including the variables listed after the “Selected Step”
do not add to the overall significance of the model. The overall adjusted r-square for the
third model was the highest at 0.257. A linear regression model utilizing the variables
that were selected in the LASSO model 3 was completed to gain insight into the
individual predictors (Table 3).
18

The relationship between the predicted REFS score and the actual REFS score can
be seen in the scatterplot in Figure 5. There is a slight positive correlation between the
predicted REFS score (as created by the LASSO model) and the actual REFS that was
measured in the BFS, however this is not statistically significant as indicated by the final
adjusted r-square (0.26).
Figure 5. Scatter plot of actual and predicted REFS
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CHAPTER 4
DISCUSSION
In this study of 762 hospitalized patients over the age of 65 years old, we found
that a frailty prediction model that included ICD codes only had a poor prediction ability
(r-square = 0.10). The prediction ability improved 2-fold after adding demographic
information, a comorbidity score and interaction terms (r-square = 0.26). This study
provided additional insights into the development of an automatic frailty assessment,
something which is currently missing from clinical care.
4.1 Comparison with prior literature
Several previous studies attempted to develop frailty prediction models, however
most often they focused on outcomes that are related to frailty (e.g., mortality or
readmission) but did not utilize a validated, in-person assessment of frailty, such as the
REFS, and instead utilized other claims data to define frailty outcomes7,10,16. This
research was also completed outside of the United States7,16 highlighting a gap in
generalizability that is addressed by the current project. Only one prior study developed a
claims-based frailty indicator anchored to a well-established frailty phenotype (Fried
frailty phenotype measured in the cardiovascular health study).7 However, this study
included only Medicare patients and utilized outpatient claims data.7 The only other study
that developed a hospital frailty risk score using data from EHR was done in UK and may
not reflect accurately the US population characteristics.16
We attempted to predict an actual, validated measure of frailty utilizing data
available in the EHR. Utilizing only data that is already available in the EHR and would
not require additional questionnaires or other clinical measures, would make it easier to
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complete risk assessments for frail individuals. These clinical risk assessments could then
lead to targeted intervention and care to frail patients, ultimately lowering readmissions,
hospitalizations, and deaths.
4.2 Strengths and limitations
The major strength of this study compared to others is the large population size
and utilizing an in-person, validated assessment of frailty as the outcome. Further, this
study utilized rigorous methodology using LASSO regression for model development and
validation. Some limitations of the study include that it only included a population from a
single, large academic medical center. In addition, non-English speaking individuals were
also excluded. While this study was completed at a single, academic institution, we
anticipate that the results would still be generalizable due to the large sample size and
rigorous methodology.
4.3 Future directions
While these prediction models were shown to be weak, it still provides critical
information for the development of a clinical frailty tool. The results showed that there
were strong relationships between depression and age, both separately and combined,
relating to frailty. Knowing that depression has a strong relationship to frailty provides
insight into a potential area for intervention. This project supports the notion older
individuals have higher rates of depression and this was associated with frailty. Providers
and healthcare personnel may be able to provide early interventions to help quell the
development of depression in older populations and as such, potentially have an impact
on an individual’s frailty, which could then lead to less admissions to the hospital and
even lower mortality rates as a function of frailty. Additionally, future research may look
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to utilize other clinically available variables, such as laboratory values, vital signs, home
medications, prescriptions, etc. and not just ICD codes in prediction models. It could also
to be important to look at variables outside of those available in the EHR to define frailty.
Our study looked at clinical variables and comorbid conditions, and perhaps frailty is
more than the sum of those variables. Future research could also aim to assess
relationships of non-clinical variables to the outcome of frailty.
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APPENDICES
APPENDIX A: ICD Codes in Frailty Domains
Frailty Domain
Debility Problems
Fatigue Issues

Swallowing Issues

Nutrition Issues

ICD-9/ICD 10 Code and Description
799.3 DEBILITY NOS
R54 Age-related physical debility
780.79 MALAISE AND FATIGUE NEC
R53.1 Weakness
R53.81 Other malaise
M62.81 Muscle weakness (generalized)
728.87 MUSCLE WEAKNESS-GENERAL
729.1 MYALGIA AND MYOSITIS NOS
787.20 DYSPHAGIA NOS
787.22 DYSPHAGIA, OROPHARYNGEAL
R13.10 Dysphagia, unspecified
R13.13 Dysphagia, pharyngeal phase
527.7 SALIVARY SECRETION DIS
530.0 ACHALASIA & CARDIOSPASM
530.10 ESOPHAGITIS, UNSPECIFIED
530.11 REFLUX ESOPHAGITIS
530.19 OTHER ESOPHAGITIS
530.3 ESOPHAGEAL STRICTURE
530.5 DYSKINESIA OF ESOPHAGUS
530.81 ESOPHAGEAL REFLUX
530.85 BARRETT'S ESOPHAGUS
530.89 OTHER DSRDERS ESOPHAGUS
J69.0 Pneumonitis due to inhalation of food and vomit
261 NUTRITIONAL MARASMUS
262 OTH SEVERE MALNUTRITION
263.0 MALNUTRITION MOD DEGREE
263.9 PROTEIN-CAL MALNUTR NOS
265.1 THIAMINE DEFIC NEC/NOS
266.2 B-COMPLEX DEFIC NEC
268.9 VITAMIN D DEFICIENCY NOS
270.6 DIS UREA CYCLE METABOL
271.3 DISACCHARIDASE DEF/MALAB
272.0 PURE HYPERCHOLESTEROLEM
272.1 PURE HYPERGLYCERIDEMIA
272.2 MIXED HYPERLIPIDEMIA
272.4 HYPERLIPIDEMIA NEC/NOS
273.1 MONOCLON PARAPROTEINEMIA
E11.9 Type 2 diabetes mellitus without complications
579.0 CELIAC DISEASE
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249.00 SEC DM WO CMP NT ST UNCN
250.00 DMII WO CMP NT ST UNCNTR
250.02 DMII WO CMP UNCNTRLD
250.03 DMI WO CMP UNCNTRLD
250.13 DMI KETOACD UNCONTROLD
250.20 DMII HPRSM NT ST UNCNTRL
250.40 DMII RENL NT ST UNCNTRLD
250.42 DMII RENAL UNCNTRLD
250.43 DMI RENAL UNCNTRLD
250.50 DMII OPHTH NT ST UNCNTRL
250.51 DMI OPHTH NT ST UNCNTRLD
250.52 DMII OPHTH UNCNTRLD
250.60 DMII NEURO NT ST UNCNTRL
250.62 DMII NEURO UNCNTRLD
250.70 DMII CIRC NT ST UNCNTRLD
250.72 DMII CIRC UNCNTRLD
250.80 DMII OTH NT ST UNCNTRLD
250.81 DMI OTH NT ST UNCNTRLD
250.82 DMII OTH UNCNTRLD
251.2 HYPOGLYCEMIA NOS
783.21 ABNORMAL LOSS OF WEIGHT
783.22 UNDERWEIGHT
Z79.4 Long term (current) use of insulin
Z68.1 Body mass index [BMI] 19.9 or less, adult
V85.0 BMI LESS THAN 19,ADULT
R68.81 Early satiety
R73.01 Impaired fasting glucose
R73.03 Prediabetes
R73.9 Hyperglycemia, unspecified
R63.0 Anorexia
R63.1 Polydipsia
R63.4 Abnormal weight loss
R64 Cachexia
E43 Unspecified severe protein-calorie malnutrition
E44.0 Moderate protein-calorie malnutrition
E44.1 Mild protein-calorie malnutrition
E46 Unspecified protein-calorie malnutrition
E53.8 Deficiency of other specified B group vitamins
E53.9 Vitamin B deficiency, unspecified
E55.9 Vitamin D deficiency, unspecified
E10.21 Type 1 diabetes mellitus with diabetic nephropathy
E10.22 Type 1 diabetes mellitus w diabetic chronic kidney
disease
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E10.319 Type 1 diabetes w unsp diabetic rtnop w/o macular
edema
E10.43 Type 1 diabetes w diabetic autonomic
(poly)neuropathy
E10.51 Type 1 diabetes w diabetic peripheral angiopath w/o
gangrene
E10.649 Type 1 diabetes mellitus with hypoglycemia without
coma
E10.65 Type 1 diabetes mellitus with hyperglycemia
E11.21 Type 2 diabetes mellitus with diabetic nephropathy
E11.22 Type 2 diabetes mellitus w diabetic chronic kidney
disease
E11.29 Type 2 diabetes mellitus w oth diabetic kidney
complication
E11.319 Type 2 diabetes w unsp diabetic rtnop w/o macular
edema
E11.329 Type 2 diab w mild nonprlf diabetic rtnop w/o
macular edema
E11.3299 Type 2 diab with mild nonp rtnop without macular
edema, unsp
E11.39 Type 2 diabetes w oth diabetic ophthalmic
complication
E11.40 Type 2 diabetes mellitus with diabetic neuropathy,
unsp
E11.42 Type 2 diabetes mellitus with diabetic polyneuropathy
E11.51 Type 2 diabetes w diabetic peripheral angiopath w/o
gangrene
E11.52 Type 2 diabetes w diabetic peripheral angiopathy w
gangrene
E11.610 Type 2 diabetes mellitus w diabetic neuropathic
arthropathy
E11.628 Type 2 diabetes mellitus with other skin
complications
E11.649 Type 2 diabetes mellitus with hypoglycemia without
coma
E11.65 Type 2 diabetes mellitus with hyperglycemia
E11.69 Type 2 diabetes mellitus with other specified
complication
E11.8 Type 2 diabetes mellitus with unspecified complications
E13.10 Oth diabetes mellitus with ketoacidosis without coma
E13.628 Oth diabetes mellitus with other skin complications
E13.69 Oth diabetes mellitus with other specified complication
E16.2 Hypoglycemia, unspecified
783.0 ANOREXIA
783.5 POLYDIPSIA
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Cognitive Issues

Acute Confusion States

783.6 POLYPHAGIA
R62.7 Adult failure to thrive
F01.50 Vascular dementia without behavioral disturbance
F01.51 Vascular dementia with behavioral disturbance
F02.80 Dementia in oth diseases classd elswhr w/o behavrl
disturb
F02.81 Dementia in oth diseases classd elswhr w behavioral
disturb
F03.90 Unspecified dementia without behavioral disturbance
F03.91 Unspecified dementia with behavioral disturbance
F05 Delirium due to known physiological condition
F09 Unsp mental disorder due to known physiological
condition
G30.9 Alzheimer's disease, unspecified
G31.83 Dementia with Lewy bodies
G31.84 Mild cognitive impairment, so stated
I69.320 Aphasia following cerebral infarction
I69.31 Cognitive deficits following cerebral infarction
I69.920 Aphasia following unspecified cerebrovascular disease
797 SENILITY W/O PSYCHOSIS
R47.01 Aphasia
331.0 ALZHEIMER'S DISEASE
331.19 FRONTOTEMP DEMENTIA NEC
331.4 OBSTRUCTIV HYDROCEPHALUS
331.82 DEMENTIA W LEWY BODIES
331.83 MILD COGNITIVE IMPAIREMT
784.3 APHASIA
780.93 MEMORY LOSS
F19.939 Other psychoactive substance use, unsp with
withdrawal, unsp
F22 Delusional disorders
F23 Brief psychotic disorder
F31.2 Bipolar disord, crnt episode manic severe w psych
features
R41.0 Disorientation, unspecified
R41.82 Altered mental status, unspecified
850.0 CONCUSSION W/O COMA
850.11 CONCUS-BRIEF COMA <31 MN
850.5 CONCUSSION W COMA NOS
850.9 CONCUSSION NOS
780.97 ALTERED MENTAL STATUS
780.09 OTHER ALTER CONSCIOUSNES
780.1 HALLUCINATIONS
780.2 SYNCOPE AND COLLAPSE
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Incontinence

Chronic Skin Ulcers

780.4 DIZZINESS AND GIDDINESS
N39.3 Stress incontinence (female) (male)
N39.41 Urge incontinence
N39.46 Mixed incontinence
N39.498 Other specified urinary incontinence
R32 Unspecified urinary incontinence
R15.9 Full incontinence of feces
N39.0 Urinary tract infection, site not specified
N39.3 Stress incontinence (female) (male)
N39.41 Urge incontinence
N39.46 Mixed incontinence
N39.498 Other specified urinary incontinence
788.30 URINARY INCONTINENCE NOS
788.31 URGE INCONTINENCE
788.41 URINARY FREQUENCY
788.42 POLYURIA
788.43 NOCTURIA
788.63 URGENCY OF URINATION
788.69 OTH ABNORMALT URINATION
787.60 FULL INCONTINENCE-FECES
E10.622 Type 1 diabetes mellitus with other skin ulcer
E11.621 Type 2 diabetes mellitus with foot ulcer
I70.245 Athscl native arteries of left leg w ulceration oth prt
foot
I83.019 Varicose veins of right lower extremity w ulcer of
unsp site
I83.208 Varicos vn unsp low extrm w ulc oth prt low extrm
and inflam
K25.4 Chronic or unspecified gastric ulcer with hemorrhage
K25.9 Gastric ulcer, unsp as acute or chronic, w/o hemor or
perf
K26.0 Acute duodenal ulcer with hemorrhage
K26.4 Chronic or unspecified duodenal ulcer with hemorrhage
K26.9 Duodenal ulcer, unsp as acute or chronic, w/o hemor or
perf
K27.7 Chronic peptic ulcer, site unsp, w/o hemorrhage or perf
K27.9 Peptic ulc, site unsp, unsp as ac or chr, w/o hemor or
perf
L89.110 Pressure ulcer of right upper back, unstageable
L89.152 Pressure ulcer of sacral region, stage 2
L89.153 Pressure ulcer of sacral region, stage 3
L89.154 Pressure ulcer of sacral region, stage 4
L89.324 Pressure ulcer of left buttock, stage 4
L89.611 Pressure ulcer of right heel, stage 1
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Sensory Impairment

L89.890 Pressure ulcer of other site, unstageable
L97.411 Non-prs chr ulcer of right heel and midft lmt to
brkdwn skin
L97.422 Non-prs chr ulcer of left heel and midfoot w fat layer
expos
L97.519 Non-prs chronic ulcer oth prt right foot w unsp
severity
L97.521 Non-prs chronic ulcer oth prt l foot limited to brkdwn
skin
L97.529 Non-pressure chronic ulcer oth prt left foot w unsp
severity
L97.819 Non-pressure chronic ulcer oth prt r low leg w unsp
severity
L97.829 Non-pressure chronic ulcer oth prt l low leg w unsp
severity
L97.919 Non-prs chronic ulc unsp prt of r low leg w unsp
severity
L97.929 Non-prs chronic ulc unsp prt of l low leg w unsp
severity
Z87.11 Personal history of peptic ulcer disease
707.24 PRESSURE ULCER, STAGE IV
707.22 PRESSURE ULCER, STAGE II
707.21 PRESSURE ULCER, STAGE I
707.20 PRESSURE ULCER,STAGE NOS
707.10 ULCER OF LOWER LIMB NOS
707.09 PRESSURE ULCER, SITE NEC
707.00 PRESSURE ULCER, SITE NOS
707.03 PRESSURE ULCER, LOW BACK
707.05 PRESSURE ULCER, BUTTOCK
707.07 PRESSURE ULCER, HEEL
707.12 ULCER OF CALF
707.13 ULCER OF ANKLE
707.14 ULCER OF HEEL & MIDFOOT
707.15 ULCER OTHER PART OF FOOT
707.19 ULCER OTH PART LOW LIMB
707.23 PRESSURE ULCER,STAGE III
707.8 CHRONIC SKIN ULCER NEC
707.9 CHRONIC SKIN ULCER NOS
359.9 MYOPATHY NOS
362.01 DIABETIC RETINOPATHY NOS
362.03 NONPROLF DB RETNOPH NOS
362.50 MACULAR DEGENERATION NOS
362.57 DRUSEN (DEGENERATIVE)
362.60 PERIPH RETINA DEGEN NOS
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365.10 OPEN-ANGLE GLAUCOMA NOS
365.70 GLAUCOMA STAGE NOS
365.89 GLAUCOMA NEC
365.9 GLAUCOMA NOS
366.9 CATARACT NOS
368.16 PSYCHOPHYSIC VISUAL DIST
368.8 VISUAL DISTURBANCES NEC
369.00 BOTH EYES BLIND-WHO DEF
369.4 LEGAL BLINDNESS-USA DEF
369.60 BLINDNESS, ONE EYE
369.8 VISUAL LOSS, ONE EYE NOS
369.9 VISUAL LOSS NOS
373.11 HORDEOLUM EXTERNUM
376.33 ORBITAL EDEMA
377.41 ISCHEMIC OPTIC NEUROPTHY
378.53 FOURTH NERVE PALSY
378.54 SIXTH NERVE PALSY
379.50 NYSTAGMUS NOS
382.9 OTITIS MEDIA NOS
383.00 AC MASTOIDITIS W/O COMPL
383.9 MASTOIDITIS NOS
386.00 MENIERE'S DISEASE NOS
386.10 PERIPHERAL VERTIGO NOS
388.01 PRESBYACUSIS
389.10 SENSORNEUR HEAR LOSS NOS
389.8 HEARING LOSS NEC
389.9 HEARING LOSS NOS
Z98.41 Cataract extraction status, right eye
Z98.42 Cataract extraction status, left eye
Z98.49 Cataract extraction status, unspecified eye
Z97.0 Presence of artificial eye
H26.9 Unspecified cataract
H35.30 Unspecified macular degeneration
H40.20X0 Unsp primary angle-closure glaucoma, stage
unspecified
H40.9 Unspecified glaucoma
H47.20 Unspecified optic atrophy
H53.2 Diplopia
H53.421 Scotoma of blind spot area, right eye
H54.0 Blindness, both eyes
H54.41 Blindness, right eye, normal vision left eye
H54.42 Blindness, left eye, normal vision right eye
H54.8 Legal blindness, as defined in USA
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Impaired Mobility

H57.12 Ocular pain, left eye
H57.8 Other specified disorders of eye and adnexa
H59.312 Postproc hemor of left eye and adnexa fol an opth
procedure
R42 Dizziness and giddiness
R44.1 Visual hallucinations
H90.5 Unspecified sensorineural hearing loss
H91.90 Unspecified hearing loss, unspecified ear
H91.91 Unspecified hearing loss, right ear
H91.93 Unspecified hearing loss, bilateral
H05.20 Unspecified exophthalmos
H61.22 Impacted cerumen, left ear
H81.09 Meniere's disease, unspecified ear
H81.10 Benign paroxysmal vertigo, unspecified ear
Z99.3 Dependence on wheelchair
Z96.611 Presence of right artificial shoulder joint
Z96.641 Presence of right artificial hip joint
Z96.642 Presence of left artificial hip joint
Z96.643 Presence of artificial hip joint, bilateral
Z96.649 Presence of unspecified artificial hip joint
Z96.651 Presence of right artificial knee joint
Z96.652 Presence of left artificial knee joint
Z96.653 Presence of artificial knee joint, bilateral
Z96.659 Presence of unspecified artificial knee joint
Z96.89 Presence of other specified functional implants
G20 Parkinson's disease
G25.0 Essential tremor
G25.81 Restless legs syndrome
M13.822 Other specified arthritis, left elbow
M13.871 Other specified arthritis, right ankle and foot
M13.872 Other specified arthritis, left ankle and foot
M13.88 Other specified arthritis, other site
M16.0 Bilateral primary osteoarthritis of hip
M16.10 Unilateral primary osteoarthritis, unspecified hip
M17.0 Bilateral primary osteoarthritis of knee
M17.11 Unilateral primary osteoarthritis, right knee
M17.12 Unilateral primary osteoarthritis, left knee
M17.9 Osteoarthritis of knee, unspecified
M19.011 Primary osteoarthritis, right shoulder
M19.039 Primary osteoarthritis, unspecified wrist
M19.041 Primary osteoarthritis, right hand
M19.042 Primary osteoarthritis, left hand
M19.049 Primary osteoarthritis, unspecified hand
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M19.079 Primary osteoarthritis, unspecified ankle and foot
M19.90 Unspecified osteoarthritis, unspecified site
R26.89 Other abnormalities of gait and mobility
214.8 LIPOMA NEC
357.2 NEUROPATHY IN DIABETES
278.00 OBESITY NOS
278.01 MORBID OBESITY
278.02 OVERWEIGHT
278.03 OBESITY HYPOVENT SYND
356.1 PERONEAL MUSCLE ATROPHY
443.9 PERIPH VASCULAR DIS NOS
Z99.81 Dependence on supplemental oxygen
Z74.01 Bed confinement status
Z68.26 Body mass index [BMI] 26.0-26.9, adult
Z68.27 Body mass index [BMI] 27.0-27.9, adult
Z68.28 Body mass index [BMI] 28.0-28.9, adult
Z68.29 Body mass index [BMI] 29.0-29.9, adult
Z68.30 Body mass index [BMI]30.0-30.9, adult
Z68.31 Body mass index [BMI] 31.0-31.9, adult
Z68.32 Body mass index [BMI] 32.0-32.9, adult
Z68.33 Body mass index [BMI] 33.0-33.9, adult
Z68.34 Body mass index [BMI] 34.0-34.9, adult
Z68.35 Body mass index [BMI] 35.0-35.9, adult
Z68.36 Body mass index [BMI] 36.0-36.9, adult
Z68.37 Body mass index [BMI] 37.0-37.9, adult
Z68.38 Body mass index [BMI] 38.0-38.9, adult
Z68.39 Body mass index [BMI] 39.0-39.9, adult
Z68.41 Body mass index [BMI]40.0-44.9, adult
Z68.42 Body mass index [BMI] 45.0-49.9, adult
Z68.43 Body mass index [BMI] 50.0-59.9, adult
Z68.44 Body mass index [BMI] 60.0-69.9, adult
V85.23 BMI 27.0-27.9,ADULT
V85.24 BMI 28.0-28.9,ADULT
V85.25 BMI 29.0-29.9,ADULT
V85.30 BMI 30.0-30.9,ADULT
V85.31 BMI 31.0-31.9,ADULT
V85.32 BMI 32.0-32.9,ADULT
V85.33 BMI 33.0-33.9,ADULT
V85.34 BMI 34.0-34.9,ADULT
V85.35 BMI 35.0-35.9,ADULT
V85.36 BMI 36.0-36.9,ADULT
V85.37 BMI 37.0-37.9,ADULT
V85.38 BMI 38.0-38.9,ADULT
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Depression Problems

V85.39 BMI 39.0-39.9,ADULT
V85.41 BMI 40.0-44.9, ADULT
V85.42 BMI 45.0-49.9, ADULT
V85.43 BMI 50.0-59.9, ADULT
V85.45 BMI 70 AND OVER, ADULT
V46.11 RESPIRATOR DEPEND STATUS
V46.2 DEPEND-SUPPLEMENT OXYGEN
V46.3 WHEELCHAIR DEPENDENCE
V49.71 STATUS AMPUT GREAT TOE
V49.72 STATUS AMPUT OTHR TOE(S)
V49.73 STATUS AMPUT FOOT
V49.75 STATUS AMPUT BELOW KNEE
V49.76 STATUS AMPUT ABOVE KNEE
V49.84 BED CONFINEMENT STATUS
R26.2 Difficulty in walking, not elsewhere classified
R26.81 Unsteadiness on feet
R27.0 Ataxia, unspecified
I73.89 Other specified peripheral vascular diseases
I73.9 Peripheral vascular disease, unspecified
G82.20 Paraplegia, unspecified
E66.01 Morbid (severe) obesity due to excess calories
E66.2 Morbid (severe) obesity with alveolar hypoventilation
E66.3 Overweight
E66.9 Obesity, unspecified
781.2 ABNORMALITY OF GAIT
781.3 LACK OF COORDINATION
714.0 RHEUMATOID ARTHRITIS
714.9 INFLAMM POLYARTHROP NOS
715.15 LOC PRIM OSTEOART-PELVIS
715.31 LOC OSTEOARTH NOS-SHLDER
715.32 LOC OSTEOARTH NOS-UP/ARM
715.34 LOC OSTEOARTH NOS-HAND
715.35 LOC OSTEOARTH NOS-PELVIS
715.36 LOC OSTEOARTH NOS-L/LEG
715.38 LOC OSTEOAR NOS-SITE NEC
715.90 OSTEOARTHROS NOS-UNSPEC
715.91 OSTEOARTHROS NOS-SHLDER
715.95 OSTEOARTHROS NOS-PELVIS
715.96 OSTEOARTHROS NOS-L/LEG
344.1 PARAPLEGIA NOS
290.0 SENILE DEMENTIA UNCOMP
290.40 VASCULAR DEMENTIA,UNCOMP
290.41 VASC DEMENTIA W DELIRIUM
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291.0 DELIRIUM TREMENS
291.2 ALCOHOL PERSIST DEMENTIA
292.81 DRUG-INDUCED DELIRIUM
293.0 DELIRIUM D/T OTHER COND
293.83 MOOD DISORDER OTHER DIS
293.9 TRANSIENT MENTAL DIS NOS
294.10 DEMENTIA W/O BEHAV DIST
294.11 DEMENTIA W BEHAVIOR DIST
294.20 DEMEN NOS W/O BEHV DSTRB
294.21 DEMEN NOS W BEHAV DISTRB
295.90 SCHIZOPHRENIA NOS-UNSPEC
296.20 DEPRESS PSYCHOSIS-UNSPEC
296.24 DEPR PSYCHOS-SEV W PSYCH
296.30 RECURR DEPR PSYCHOS-UNSP
296.44 BIPOL I MANIC-SEV W PSY
296.80 BIPOLAR DISORDER NOS
296.89 BIPOLAR DISORDER NEC
296.90 EPISODIC MOOD DISORD NOS
297.1 DELUSIONAL DISORDER
298.9 PSYCHOSIS NOS
300.00 ANXIETY STATE NOS
300.01 PANIC DIS W/O AGORPHOBIA
300.02 GENERALIZED ANXIETY DIS
300.22 AGORAPHOBIA W/O PANIC
300.3 OBSESSIVE-COMPULSIVE DIS
300.4 DYSTHYMIC DISORDER
301.83 BORDERLINE PERSONALITY
303.90 ALCOH DEP NEC/NOS-UNSPEC
309.0 ADJUSTMNT DIS W DEPRESSN
309.81 POSTTRAUMATIC STRESS DIS
311 DEPRESSIVE DISORDER NEC
F31.9 Bipolar disorder, unspecified
F32.9 Major depressive disorder, single episode, unspecified
F33.1 Major depressive disorder, recurrent, moderate
F33.41 Major depressive disorder, recurrent, in partial
remission
F39 Unspecified mood [affective] disorder
F41.0 Panic disorder [episodic paroxysmal anxiety]
F41.1 Generalized anxiety disorder
F41.8 Other specified anxiety disorders
F41.9 Anxiety disorder, unspecified
F43.10 Post-traumatic stress disorder, unspecified
F43.21 Adjustment disorder with depressed mood
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Falls

Fractures

F43.22 Adjustment disorder with anxiety
E880.9 FALL ON STAIR/STEP NEC
E881.0 FALL FROM LADDER
E884.2 FALL FROM CHAIR
E884.3 FALL FROM WHEELCHAIR
E884.4 FALL FROM BED
E884.6 FALL FROM COMMODE
E884.9 FALL-1 LEVEL TO OTH NEC
E885.9 FALL FROM SLIPPING NEC
E888.1 FALL STRIKING OBJECT NEC
E888.8 FALL NEC
E888.9 FALL NOS
E917.9 OBJ W-W/O SUB FALL NEC
E918 CAUGHT BETWEEN OBJECTS
E929.3 LATE EFF ACCIDENTAL FALL
Z91.81 History of falling
R29.6 Repeated falls
W01.0XXA Fall same lev from slip/trip w/o strike against
object, init
W05.0XXA Fall from non-moving wheelchair, initial
encounter
W06.XXXA Fall from bed, initial encounter
W06.XXXD Fall from bed, subsequent encounter
W18.09XA Striking against oth object w subsequent fall, init
encntr
W18.11XA Fall from or off toilet w/o strike against object, init
W18.30XA Fall on same level, unspecified, initial encounter
W18.39XA Other fall on same level, initial encounter
W19.XXXA Unspecified fall, initial encounter
W19.XXXD Unspecified fall, subsequent encounter
S22.000A Wedge compression fracture of unsp thoracic
vertebra, init
S22.079A Unsp fracture of T9-T10 vertebra, init for clos fx
S22.31XA Fracture of one rib, right side, init for clos fx
S22.41XA Multiple fractures of ribs, right side, init for clos fx
S32.018A Oth fracture of first lumbar vertebra, init for clos fx
S32.019A Unsp fracture of first lumbar vertebra, init for clos
fx
S32.028A Oth fracture of second lumbar vertebra, init for clos
fx
S42.009A Fracture of unsp part of unsp clavicle, init for clos
fx
S42.309D Unsp fx shaft of humerus, unsp arm, subs for fx w
routn heal
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S52.502A Unsp fracture of the lower end of left radius, init
S72.011A Unsp intracapsular fracture of right femur, init for
clos fx
S72.22XA Displaced subtrochanteric fracture of left femur,
init
S72.91XD Unsp fracture of right femur, subs for clos fx w
routn heal
S92.312A Disp fx of first metatarsal bone, left foot, init
S92.322A Disp fx of second metatarsal bone, left foot, init
S92.332A Disp fx of third metatarsal bone, left foot, init
S92.342A Disp fx of fourth metatarsal bone, left foot, init
S92.902A Unsp fracture of left foot, init encntr for closed
fracture
V13.51 HX PATHOLOGICAL FRACTURE
V15.51 HX TRAUMATIC FRACTURE
733.81 MALUNION OF FRACTURE
733.82 NONUNION OF FRACTURE
733.94 STRESS FX METATARSALS
733.12 PATH FX DSTL RADIUS ULNA
733.13 PATH FX VERTEBRAE
733.14 PATH FX NECK OF FEMUR
733.16 PATH FX TIBIA FIBULA
733.19 PATH FX OTH SPECIF SITE
802.0 NASAL BONE FX-CLOSED
805.00 FX CERVICAL VERT NOS-CL
805.02 FX C2 VERTEBRA-CLOSED
805.2 FX DORSAL VERTEBRA-CLOSE
805.4 FX LUMBAR VERTEBRA-CLOSE
807.00 FRACTURE RIB NOS-CLOSED
807.01 FRACTURE ONE RIB-CLOSED
807.03 FRACTURE THREE RIBS-CLOS
807.04 FRACTURE FOUR RIBS-CLOSE
807.05 FRACTURE FIVE RIBS-CLOSE
807.06 FRACTURE SIX RIBS-CLOSED
807.07 FRACTURE SEVEN RIBS-CLOS
807.09 FX MULT RIBS NOS-CLOSED
807.2 FRACTURE OF STERNUM-CLOS
808.0 FRACTURE ACETABULUM-CLOS
808.2 FRACTURE OF PUBIS-CLOSED
808.44 PELV FX-CL W/O PLV DISRP
808.8 PELVIC FRACTURE NOS-CLOS
811.03 FX SCAP, GLEN CAV/NCK-CL
812.00 FX UP END HUMERUS NOS-CL
812.01 FX SURG NCK HUMERUS-CLOS
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812.03 FX GR TUBEROS HUMERUS-CL
812.20 FX HUMERUS NOS-CLOSED
812.21 FX HUMERUS SHAFT-CLOSED
812.40 FX LOWER HUMERUS NOS-CL
813.01 FX OLECRAN PROC ULNA-CL
813.13 MONTEGGIA'S FX-OPEN
813.42 FX DISTAL RADIUS NEC-CL
813.44 FX LOW RADIUS W ULNA-CL
813.83 FX RADIUS W ULNA NOS-CL
815.01 FX 1ST METACARP BASE-CL
816.02 FX DIST PHALANX, HAND-CL
820.00 FX FEMUR INTRCAPS NOS-CL
820.03 FX BASE FEMORAL NCK-CLOS
820.09 FX FEMUR INTRCAPS NEC-CL
820.20 TROCHANTERIC FX NOS-CLOS
820.21 INTERTROCHANTERIC FX-CL
820.22 SUBTROCHANTERIC FX-CLOSE
820.8 FX NECK OF FEMUR NOS-CL
821.00 FX FEMUR NOS-CLOSED
821.01 FX FEMUR SHAFT-CLOSED
821.20 FX LOW END FEMUR NOS-CL
821.22 FX LOW FEMUR EPIPHY-CLOS
821.23 SUPRACONDYL FX FEMUR-CL
821.29 FX LOW END FEMUR NEC-CL
822.0 FRACTURE PATELLA-CLOSED
823.00 FX UPPER END TIBIA-CLOSE
823.01 FX UPPER END FIBULA-CLOS
823.02 FX UP TIBIA W FIBULA-CL
823.20 FX SHAFT TIBIA-CLOSED
823.22 FX SHAFT FIB W TIB-CLOS
823.80 FX TIBIA NOS-CLOSED
824.4 FX BIMALLEOLAR-CLOSED
824.5 FX BIMALLEOLAR-OPEN
824.6 FX TRIMALLEOLAR-CLOSED
824.8 FX ANKLE NOS-CLOSED
825.21 FX ASTRAGALUS-CLOSED
825.25 FX METATARSAL-CLOSED
825.31 FX ASTRAGALUS-OPEN
829.0 FRACTURE NOS-CLOSED
E887 FRACTURE, CAUSE NOS
M80.08XA Age-rel osteopor w current path fracture,
vertebra(e), init
M80.88XA Oth osteopor w current path fracture, vertebra(e),
init
36

Anemia

M81.0 Age-related osteoporosis w/o current pathological
fracture
M84.40XA Pathological fracture, unsp site, init encntr for
fracture
M84.444A Pathological fracture, right finger(s), init for fx
M84.48XA Pathological fracture, other site, init encntr for
fracture
M84.58XA Pathological fracture in neoplastic disease, oth site,
init
V54.12 AFTRCRE TRAUM FX LOW ARM
905.2 LATE EFFECT ARM FX
905.4 LATE EFFECT LEG FX
996.44 PERIPROSTHETC FX-PROS JT
280.0 CHR BLOOD LOSS ANEMIA
280.8 IRON DEFIC ANEMIA NEC
280.9 IRON DEFIC ANEMIA NOS
281.0 PERNICIOUS ANEMIA
281.1 B12 DEFIC ANEMIA NEC
281.9 DEFICIENCY ANEMIA NOS
283.0 AUTOIMMUN HEMOLYTIC ANEM
285.1 AC POSTHEMORRHAG ANEMIA
285.21 ANEMIA IN CHR KIDNEY DIS
285.22 ANEMIA IN NEOPLASTIC DIS
285.29 ANEMIA-OTHER CHRONIC DIS
285.3 ANEMIA D/T ANTINEO CHEMO
285.8 ANEMIA NEC
285.9 ANEMIA NOS
D46.21 Refractory anemia with excess of blasts 1
D50.0 Iron deficiency anemia secondary to blood loss
(chronic)
D50.9 Iron deficiency anemia, unspecified
D51.0 Vitamin B12 defic anemia due to intrinsic factor
deficiency
D53.8 Other specified nutritional anemias
D53.9 Nutritional anemia, unspecified
D58.9 Hereditary hemolytic anemia, unspecified
D62 Acute posthemorrhagic anemia
D63.1 Anemia in chronic kidney disease
D63.8 Anemia in other chronic diseases classified elsewhere
D64.81 Anemia due to antineoplastic chemotherapy
D64.9 Anemia, unspecified
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